Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has 2 licensing announcements in this dataset, dated 2026-03-04 to 2026-07-08.
- Country / operating region
- China
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.cttq.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Rovadicitinib | JAK; ROCK | small molecule | approved | 2026-03-04 |
| TQC3721 | PDE3; PDE4 | small molecule | phase3 | 2026-07-08 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Sanofi | Rovadicitinib | USD 135m | 查無 | 查無 | ≤ USD 1530m | Payment recipient Sino Biopharmaceutical Limited (SBP Group) |
| 2026-07-08 | AstraZeneca | TQC3721 | USD 200m | 查無 | 查無 | 查無 | Payment recipient Sino Biopharmaceutical Limited (SBP Group) |
| Counterparty | Territory | Royalties |
|---|---|---|
| Sanofi | Worldwide | Tiered royalties up to double digits on annual net sales. |
| AstraZeneca | Outside China; certain agreed development plans carry worldwide rights | Tiered royalties up to double-digit percentages on annual net sales. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無